ArticleHaematologica2020
Prognostic value of FDG-PET in patients with mantle cell lymphoma: results from the LyMa-PET Project.
Article in Haematologica, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Cellular therapy in mantle cell lymphoma: recommendations from the EBMT practice harmonisation and guidelines committee.Bone marrow transplantation · 2026Guideline
- Circulating tumor DNA predicts therapeutic outcome in mantle cell lymphoma.Blood advances · 2022Trial
- The SPECT/CT radiomics-based classification of skeletal metastases and benign bone lesions.Scientific reports · 2026Article
- Prognostic Role of Pretreatment Tumor Burden and Dissemination Features From 2-[Hematological oncology · 2025Article
- Article
- Long-Axial Field-of-View PET Imaging in Patients with Lymphoma: Challenges and Opportunities.PET clinics · 2024Review
- Quantitative evaluation of lesion response heterogeneity for superior prognostication of clinical outcome.European journal of nuclear medicine and molecular imaging · 2024Article
- Performance of baseline FDG-PET/CT radiomics for prediction of bone marrow minimal residual disease status in the LyMa-101 trial.Scientific reports · 2023Article
- Application of the Lugano Classification for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The PRoLoG Consensus Initiative (Part 1-Clinical).Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023Article
- Prognostic value of pre-transplantation total metabolic tumor volume onInternational journal of hematology · 2022Article
- Treatment of Mantle Cell Lymphoma in the Frontline Setting: Are We Ready for a Risk-Adapted Approach?Journal of personalized medicine · 2022Review
- Deep Neural Networks and Machine Learning Radiomics Modelling for Prediction of Relapse in Mantle Cell Lymphoma.Cancers · 2022Article
- Baseline SUVmax is related to tumor cell proliferation and patient outcome in follicular lymphoma.Haematologica · 2022Article
- Prognostic Value of Heterogeneity Index Derived from BaselineFrontiers in oncology · 2022Article
- FDG-PET/CT in Lymphoma: Where Do We Go Now?Cancers · 2021Article
- Positron emission tomography and magnetic resonance imaging in primary central nervous system lymphoma-a narrative review.Annals of lymphoma · 2021Article
- Observational
- Computer-aided detection of mantle cell lymphoma onAmerican journal of nuclear medicine and molecular imaging · 2021Article
- Article
- Prognostic value ofHaematologica · 2020Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.